Developer

Convergence Pharmaceuticals

1compound
1program
1indication
Discontinuedlead asset

Phase distribution

  • Discontinued1

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Jan 12, 2015AcquisitionBiogen Idec to acquire Convergence Pharmaceuticals, gaining vixotrigine (then CNV1014802)Biogen Idec announced the acquisition of UK-based Convergence Pharmaceuticals — the 2010 GSK ion-channel spinout — for $200 million upfront plus up to $475 million in contingent milestone payments, expanding into neuropathic pain with lead asset CNV1014802 (vixotrigine), then in development for trigeminal neuralgia. The acquisition completed in February 2015; Biogen recognized $424.6 million of acquired IPR&D intangible assets for vixotrigine and a $274.5 million contingent-consideration obligation (per the FY2022 10-K, both later written to zero on the December 2022 discontinuation).Vixotriginesource ↗

Catalysts · 0 upcoming · 1 reported

Recently reported

  • 2021-09-16mixed

    VixotrigineforNeuropathic painTopline data

    Phase 2 CONVEY topline in painful small fiber neuropathy: vixotrigine 200 mg BID met the primary endpoint (change from baseline in average daily pain at Week 12 of the double-blind period, p=0.050 vs placebo); 350 mg BID did not (p=0.70).

    source ↗

Recent activity

  • Dec 31, 2022Phase changeVixotrigine·Neuropathic painDiscontinuedBiogen FY2022 Form 10-K: 'In December 2022 we discontinued further development of vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN) and diabetic painful neuropathy (DPN), based on regulatory, development and commercialization challenges.' FY2022 impairment of $119.6M (DPN) reduced the IPR&D book value to zero; the Convergence contingent-consideration obligation was adjusted to zero (~$209.1M pre-tax gain; the year's total contingent-consideration reduction related to vixotrigine was ~$195.4M net). Exact day in December 2022 not disclosed — changed_at is a month-precision anchor at 2022-12-31. The two Phase 3 registrations were withdrawn on ClinicalTrials.gov 2023-05-06. No event code exists for a program discontinuation, so this row is the canonical record of it.source ↗
  • Sep 16, 2021ReadoutVixotrigine·Neuropathic painmixedPhase 2 CONVEY topline in painful small fiber neuropathy: vixotrigine 200 mg BID met the primary endpoint (change from baseline in average daily pain at Week 12 of the double-blind period, p=0.050 vs placebo); 350 mg BID did not (p=0.70).source ↗
  • Mar 3, 2017Phase changeVixotrigine·Neuropathic painPhase 3Phase 3 trigeminal-neuralgia trial 802NP301 (NCT03070132) first posted on ClinicalTrials.gov 2017-03-03; sister study 802NP302 (NCT03637387) posted 2018-08-20. REGISTERED, NEVER ENROLLED: both ended WITHDRAWN with actual enrollment 0 ('Sponsor Decision'). Per Biogen's FY2022 10-K there were 'numerous delays in the initiation of Phase 3 studies' for TGN and DPN; Biogen engaged the FDA on Phase 3 design and ran an FDA-relevant additional clinical trial (completed during 2022) whose performance further delayed initiation, driving a $44.3M TN impairment in Q1 2021. Biogen's pipeline listed vixotrigine at Phase 3 for TN during this period; the peak phase actually dosed was Phase 2.source ↗
  • Apr 30, 2011Phase changeVixotrigine·Neuropathic painPhase 2First Phase 2 start under Convergence: the crossover study of CNV1014802 in neuropathic pain from lumbosacral radiculopathy (NCT01561027, n=82, started April 2011). The Phase 2a trigeminal-neuralgia randomized-withdrawal study (NCT01540630) followed in March 2012 and completed March 2014 (published Zakrzewska et al., Lancet Neurol 2017). Biogen acquired Convergence in February 2015 on the strength of this data (see acquisition event).source ↗
  • May 31, 2007Phase changeVixotrigine·Neuropathic painPhase 1First-in-human single-dose escalation of GSK1014802 started under GlaxoSmithKline (NCT00488566). The earliest GSK Phase 1s were registered under bipolar-disorder conditions (also NCT00908154, repeat-dose, 2008) — GSK briefly explored the mechanism in mood disorders before the ion-channel portfolio was spun out into Convergence Pharmaceuticals (2010), which repositioned the molecule (as CNV1014802) for neuropathic pain.source ↗

Competitive landscape

Other companies developing against Convergence Pharmaceuticals's targets or indications.